Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Synplogen Co., Ltd. currently has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are divided between 2 distinct examiners and 2 distinct art units. MARVICH, MARIA is the busiest examiner, handling 1 pending office action. The distribution of cases across different examiners and art units suggests that the company is pursuing multiple distinct technical paths within its current patent portfolio.
The presence of 2 distinct examiners for only 2 pending office actions ensures that each case receives an independent evaluation. Because these cases are also located in 2 distinct art units, the company is likely testing different technical aspects of its biotechnology platform. Practitioners should be prepared for varying examination standards and should carefully coordinate their responses to ensure that the 2 pending office actions do not result in conflicting claim scopes. This diversified approach can lead to a more resilient patent portfolio by spreading the prosecution risk across multiple administrative units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| UNDERDAHL, THANE E | 1 | 58.8% | +50.8% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251737 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | MARVICH, MARIA | 70d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251737 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | MARVICH, MARIA | 70d overdue |
| 18251792 | INTEGRATIVE PLASMID | UNDERDAHL, THANE E | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18251792 | INTEGRATIVE PLASMID | UNDERDAHL, THANE E | 1699 | §103§112DP | Non-Final OA | — | Pending | May 04, 2023 |
| 18251737 | PRODUCTION OF VIRUS VECTOR PLASMID IN BACILLUS SUBTILIS | MARVICH, MARIA | 1634 | §101§102§103§112 | Final Rejection | 70d overdue | Pending | May 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial